glp 1 agonist news GLP-1 drugs promise wider health benefits, but experts urge caution on use Glucagon-Like Peptide-1 Receptor Agonists in

They are now commonly used when: Metformin alone is no longer enough Weight gain is contributing to worsening glucose control There is a need to minimise hypoglycaemia risk Someone has existing cardiovascular disease or multiple risk factors For many people, GLP-1 therapy can delay or reduce the need for insulin, or allow insulin doses to be kept lower and safer

Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial

Changing the conversation about obesity For both researchers, one of the most important impacts of GLP-1 drugs may be how they reshape public understanding of obesity itself

It is vital to focus on high-protein, nutrient-dense foods if you are using any weight loss tool while postpartum

12.9%, adjusted HR [aHR]: 0.57, 95% CI 0.51, 0.64), MACE (14.8% vs